Literature DB >> 30144541

APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.

Shanshan Wang1, Jie Zhang2, Tengwei Pan3.   

Abstract

The underlying mechanism of apolipoprotein E ε4 (APOE ε4) in the pathogenesis of Alzheimer's disease (AD) remains elusive. We hypothesize that synaptic function is differentially affected by APOE isoforms. Levels of CSF SNAP-25 were compared between APOE ε4 carriers and noncarriers in 55 participants with normal cognition, 75 patients with mild cognitive impairment (MCI), and 16 patients with mild AD dementia. We investigated relationships between SNAP-25 levels and age, gender, education, CSF Aβ42, and tau protein. We found that levels of SNAP-25 in CSF were substantially greater in APOE ε4 carriers compared to noncarriers with MCI. There was no significant difference in SNAP-25 levels between APOE ε4 carriers and noncarriers with normal cognition or AD. CSF SNAP-25 levels were associated with MMSE and CSF Aβ and tau levels. In summary, APOE ε4 may affect CSF SNAP levels in MCI patients, suggesting an important role of APOE ε4 in synaptic dysfunction leading to AD.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APOE ε4; Alzheimer’s disease; Mild cognitive impairment; SNAP-25; Synaptic function

Mesh:

Substances:

Year:  2018        PMID: 30144541     DOI: 10.1016/j.neulet.2018.08.029

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease.

Authors:  Johanna Nilsson; Nicholas J Ashton; Andrea L Benedet; Laia Montoliu-Gaya; Johan Gobom; Tharick A Pascoal; Mira Chamoun; Erik Portelius; Andreas Jeromin; Muriel Mendes; Henrik Zetterberg; Pedro Rosa-Neto; Ann Brinkmalm; Kaj Blennow
Journal:  Alzheimers Res Ther       Date:  2022-06-04       Impact factor: 8.823

2.  Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25.

Authors:  Omar H Butt; Justin M Long; Rachel L Henson; Elizabeth Herries; Courtney L Sutphen; Anne M Fagan; Carlos Cruchaga; Jack H Ladenson; David M Holtzman; John C Morris; Beau M Ances; Suzanne E Schindler
Journal:  Neurobiol Aging       Date:  2021-02-11       Impact factor: 5.133

Review 3.  Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals.

Authors:  Tian Qin; Samantha Prins; Geert Jan Groeneveld; Gerard Van Westen; Helga E de Vries; Yin Cheong Wong; Luc J M Bischoff; Elizabeth C M de Lange
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

4.  Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer's Disease.

Authors:  Catarina Perdigão; Mariana A Barata; Margarida N Araújo; Farzaneh S Mirfakhar; Jorge Castanheira; Cláudia Guimas Almeida
Journal:  Front Cell Neurosci       Date:  2020-04-17       Impact factor: 5.505

Review 5.  Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges.

Authors:  Marta Marquié; Mercè Boada; Amanda Cano; Patric Turowski; Miren Ettcheto; Jason Thomas Duskey; Giovanni Tosi; Elena Sánchez-López; Maria Luisa García; Antonio Camins; Eliana B Souto; Agustín Ruiz
Journal:  J Nanobiotechnology       Date:  2021-04-29       Impact factor: 10.435

6.  CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.

Authors:  Marta Milà-Alomà; Ann Brinkmalm; Nicholas J Ashton; Hlin Kvartsberg; Mahnaz Shekari; Grégory Operto; Gemma Salvadó; Carles Falcon; Juan Domingo Gispert; Natalia Vilor-Tejedor; Eider M Arenaza-Urquijo; Oriol Grau-Rivera; Aleix Sala-Vila; Gonzalo Sanchez-Benavides; José María González-de-Echávarri; Carolina Minguillon; Karine Fauria; Aida Niñerola-Baizán; Andrés Perissinotti; Gwendlyn Kollmorgen; Ivonne Suridjan; Henrik Zetterberg; José Luis Molinuevo; Kaj Blennow; Marc Suárez-Calvet
Journal:  Neurology       Date:  2021-09-23       Impact factor: 9.910

7.  Identification of mild cognitive impairment subtypes predicting conversion to Alzheimer's disease using multimodal data.

Authors:  Masataka Kikuchi; Kaori Kobayashi; Sakiko Itoh; Kensaku Kasuga; Akinori Miyashita; Takeshi Ikeuchi; Eiji Yumoto; Yuki Kosaka; Yasuto Fushimi; Toshihiro Takeda; Shirou Manabe; Satoshi Hattori; Akihiro Nakaya; Kenichi Kamijo; Yasushi Matsumura
Journal:  Comput Struct Biotechnol J       Date:  2022-08-22       Impact factor: 6.155

8.  Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome.

Authors:  Rachel L Henson; Eric Doran; Bradley T Christian; Benjamin L Handen; William E Klunk; Florence Lai; Joseph H Lee; H Diana Rosas; Nicole Schupf; Shahid H Zaman; Ira T Lott; Anne M Fagan
Journal:  Alzheimers Dement (Amst)       Date:  2020-07-09

Review 9.  Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer's Disease.

Authors:  Bin Zhou; Masanori Fukushima
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

Review 10.  A Comprehensive Review of Alzheimer's Association with Related Proteins: Pathological Role and Therapeutic Significance.

Authors:  Deepak Kumar; Aditi Sharma; Lalit Sharma
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.